Registries in rheumatological and musculoskeletal conditions : Paediatric Beh&#231;et&apos;s disease: an international cohort study of 110 patients : one-year follow-up data by I. Kon&#233 et al.
Concise report
Registries in rheumatological and musculoskeletal
conditions. Paediatric Behc¸et’s disease: an
international cohort study of 110 patients.
One-year follow-up data
Isabelle Kone´-Paut1, Martha Darce-Bello1, Farahd Shahram2, Marco Gattorno3,
Rolando Cimaz4, Seza Ozen5, Luca Cantarini6, Ilknur Tugal-Tutktun7,
Samir Assaad-Khalil8, Michael Hofer9, Jasmin Kuemmerle-Deschner10,
Saida Benamour11, Souleymane Al Mayouf12, Christine Pajot13, Jordi Anton14,
Albert Faye15, Wafa Bono16, Susan Nielsen17, Alexia Letierce18, Tu-Anh Tran1
and the PED-BD International Expert Committee*
Abstract
Objective. To set-up an international cohort of patients suspected with Behc¸et’s disease (BD). The cohort
is aimed at defining an algorithm for definition of the disease in children.
Methods. International experts have defined the inclusion criteria as follows: recurrent oral aphthosis
(ROA) plus one of following—genital ulceration, erythema nodosum, folliculitis, pustulous/acneiform
lesions, positive pathergy test, uveitis, venous/arterial thrombosis and family history of BD. Onset of
disease is <16 years, disease duration is 43 years, future follow-up duration is 54 years and informed
consent is obtained. The expert committee has classified the included patients into: definite paediatric BD
(PED-BD), probable PED-BD and no PED-BD. Statistical analysis is performed to compare the three
groups of patients. Centres document their patients into a single database.
Results. At January 2010, 110 patients (56 males/54 females) have been included. Mean age at first
symptom: 8.1 years (median 8.2 years). At inclusion, 38% had only one symptom associated with ROA,
31% had two and 31% had three or more symptoms. A total of 106 first evaluations have been done.
Seventeen patients underwent the first-year evaluation, and 36 had no new symptoms, 12 had one and
9 had two. Experts have examined 48 files and classified 30 as definite and 18 as probable. Twenty-six
patients classified as definite fulfilled the International Study Group criteria. Seventeen patients classified
as probable did not meet the international criteria.
Conclusion. The expert committee has classified the majority of patients in the BD group although they
presented with few symptoms independently of BD classification criteria.
Key words: Pediatric Behc¸et’s disease, Epidemiology, Cohort study, Definition of disease, Early-onset Behc¸et’s
disease, Outcome.
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Introduction
Behc¸et’s disease (BD) was initially reported under the as-
sociation of oral genital aphthous lesions plus uveitis.
Involvement of medium- and large-size vessels leads
to serious complications such as neurological and ocular
damage. Most BD cases cluster from Japan to the
Mediterranean basin along the former Silk Route. The
highest prevalence of BD is reported in Iran: 68/105,
Japan: 10–15/105 and Turkey: 42/105 [1–4]. Prevalence
is markedly lower in Western countries: 2/105 in
Germany and 2.5 /105 in Italy [5–7]. BD is usually encoun-
tered in young adults with male predominance in
Mediterranean countries. Male patients also have the
worst disease course with severe ocular, neurological
and vascular involvement [8]. Several attempts to define
BD proposed a combination of clinical manifestations,
distinguished between major and minor in accordance
with their severity and frequency [9, 10]. Diagnostic criteria
were defined by the International Study Group (ISG) for
BD in 1990 and a convincing classification tree was pro-
posed by an Iranian group in 1993 for adult patients only
[11, 12]. BD may be observed before the age of 16 years
in 4–26% of cases [5]. Data from a French epidemiological
survey conducted in 1992 indicated a prevalence of
1/600 000 children under 15 years of age; however, un-
awareness of the disease probably caused an important
subestimate [13]. In 1998, we could collect 200 paediatric
BD (PED-BD) cases, but only half of them could be con-
firmed using the international criteria [14]. This study is
aimed to set up an international cohort of patients sus-
pected with BD and selected on homogeneous criteria.
The cohort is aimed at defining an algorithm for definition
of the disease in children, also reflecting the natural
history. We present herein results from a 2-year study
with patients’ follow-up at 1 year.
Patients and methods
Study design
First step: expert consensus formation
In 2007, an international expert committee defined, using
Nominal Group Technique, homogeneous criteria for in-
clusion in the PED-BD cohort study and designed an elec-
tronic patient chart that enables international
collaboration. This committee included four adults and
three PED-BD specialists from five countries (Turkey,
Iran, Italy, Switzerland and France) (listed in Appendix),
and members of either the Paediatric Rheumatology
European Society (PRES) or the International BD Society
(ISBD).
Second step: setting-up of electronic database,
international collaboration and data entry
A web database (CleanWEB web system) was formatted
in 2008, in accordance with the anonymity of patients and
following the advice and recommendations of the
Commission Nationale Informatique et Liberte´s (CNIL).
Centres specializing in PED-BD (PRES, PRINTO and
ISBD members) have been called to register their patients
into the database. Data entry, both retrospective and pro-
spective, started in 2008. Records were selected if pa-
tients were not lost to follow-up and if they were first
seen in the participating centre within the past 3 years.
They were updated annually with the referring doctor
receiving an electronic callback.
Third step: judgement criteria
The expert committee performed charts review during the
two international meetings in order to classify patients as
definite BD, probable BD or no BD. Sharing participants in
a round-robin format collected the votes. Consensus was
obtained as an agreement among 80% of the experts.
Patients were classified as definite or no BD if consensus
was obtained. Patients without consensus were classified
as probable.
Fourth step: statistical analyses
After 2 years of study, statistical analyses were conducted
in order to determine the nature and sequence of signs in
our patients and to analyse those classified as definite BD
using the international criteria. At 4 years, these signs will
then be compared between two groups of patients:
(i) those who met the existing international criteria; and
(ii) those who have not yet achieved these criteria and
who will represent an internal control group in order to
determine their sensitivity and specificity.
Inclusion criteria
They were defined as widely as possible to avoid any
prejudice by existing criteria that will serve at the end as
gold standard for statistical analyses. They included: first
sign related to BD before the age of 16 years; new patient
or patient followed for <3 years; patient being able to be
followed for 4 years; and informed consent and ethics
committee approval (if applicable in the country).
Experts considered recurrent oral aphthosis (ROA) (more
than three attacks/year) as mandatory and being asso-
ciated with at least one of following symptoms: genital
ulceration (GU), erythema nodosum, folliculitis, pustu-
lous/acneiform lesions, positive pathergy test, uveitis, ret-
inal vasculitis, venous/arterial thrombosis and
documented family history of BD.
Information contained in the e-CRF
The electronic record (e-CRF: electronic Chart Report
Form) contained demographic items, including the ethni-
city and presence of consanguinity. A section has been
devoted to each category of symptoms, with information
on their chronology. Biological items included: inflamma-
tory markers, predisposition to thrombosis and HLA
typing.
Results
As of January 2010, 110 patients (56 males/54 females)
from 16 centres of 11 countries have been included (Fig.
1). The mean age at inclusion was 13.5 years (median 14.5
years; range 3.4–21.1 years). The mean age at first
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symptom was 8.1 years (median 8.2 years). BD was sus-
pected at a mean age of 11.8 years (median 14.4 years).
The mean delay between first symptom and BD suspicion
was 3.7 years (median 2.7 years; range 0–17 years). At
inclusion, 38% (42/110) of patients had only one symptom
associated with ROA, 31% had two and 31% had at least
three. Most frequent symptoms in addition to ROA were
GU in 61% (67/110), skin lesion in 57% (63/110) and uve-
itis in 30% (33/110). Family history of BD was present in
21 (19%) patients with consanguinity in 4 of them. Other
BD-affected relatives were as follows: mother in four
cases, father in one, uncle in three, grandfather in one
and cousin in one. Three relatives were affected in three
families: mother and aunt in two families, father and
grandfather in another. Ninety-eight per cent (106) of pa-
tients entered the study and were further analysed. Four
patients with incomplete documentation were excluded.
Fifty-six per cent (59/106) of them presented with one
symptom: of those, ROA was present in 42% (45/106).
Twenty-four per cent (26/106) had two symptoms
(ROA + GU in six of them); 17 of them had three or more
signs of BD. Four patients had no symptom at first evalu-
ation, but had presented with ROA in the past and had
familial history of BD. ROA was the presenting symptom in
83% of patients. GU was significantly associated with
female gender (P= 0.02). Cutaneous manifestations were
present in 52% (58/106) of patients (Fig. 2). They included
necrotic folliculitis in 24 (29%) patients, erythema nodo-
sum in 19 (23%), acneiform lesion in 13 (16%), skin ulcer-
ation in 7 (8%) and aphthae in 7 (8%). The pathergy test
was performed in 38 patients, and was positive in
17 (45%) of them. Thirty-six (34%) patients had a history
of uveitis: 7 with anterior uveitis only and 17 with
associated posterior uveitis (n= 15) and retinal vasculitis
(n= 2). In patients with ocular manifestations, the male
predominance (29/36) was statistically highly significant
(P= 0.0002). Seven of them had visual acuity of <1/10
with blindness in one case. Twelve patients had venous
thrombosis and one had arterial aneurysm. Neurological
signs, presented by 29/31 patients, were headaches in
most cases. Other miscellaneous neurological signs
were: long-tract dysfunction (one patient), brain stem dys-
function (one patient), optical nerve involvement (one pa-
tient), cranial nerve palsy (one patient), severe mental
state (one patient) and seizures (three patients).
Gastrointestinal symptoms in the form of abdominal pain
were reported in 28 (26%) patients. Aphthae (or ulceration)
were reported twice with digestive bleeding in one case.
Serosal inflammation was reported in seven patients:
pleuritis in three, pericarditis in three and orchitis in one.
Ninety-three per cent of patients (n= 99) were receiving
treatment. Fifty-nine per cent (n= 64) received colchicine,
58% steroids (n= 63) and 14% AZA (n= 15). HLA-B51 was
positive in 44% of patients tested (16/36). Fifty-seven pa-
tients underwent a first-year visit. Thirty-six of them had
no new symptoms, 12 had one and 9 had two. The expert
committee has examined 48 files (4 of them twice) and
classified 30 as definite and 18 as probable. In the definite
group, the mean (S.D.) age at first symptom was 9.1 (4)
years (median 9.6 years; range 1.2–15 years) and the
mean (S.D.) age at diagnostic confirmation was 14.4 (4.1)
years (median 15 years; range 7–22 years). They did not
classify any patient as no BD. Fifteen patients had two or
fewer symptoms; 11 of them were classified as probable
and 4 as definite. Thirty-three patients had three or more
symptoms, 26 being classified as definite and 7 as
FIG. 1 Distribution of 110 PED-BD patients by country and gender.
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probable. Therefore, having three or more symptoms was
significantly associated with classification as definite
BD (P= 0.0005). Among our patients classified as definite,
26/30 (87%) fulfilled the ISG criteria, while 17/18 (94%)
classified as probable did not meet the international cri-
teria. The list of main signs present in each group of pa-
tients in addition to ROA is represented in Table 1.
Discussion
This study is a first attempt to define BD in patients
before the age of 16 years. Patients registered to the
database were expected to have a clinical suspicion of
BD, but they were not required to meet any international
classification or diagnostic criteria. An international effort
has been made to obtain consensus on homogeneous
inclusion criteria and to collect information prospectively.
Inclusion criteria were deliberately chosen large enough
so as to miss the fewest possible patients who may have
BD. The group of experts considered ROA as manda-
tory, since this sign is present in >95% of patients
with BD. Moreover, ROA is the most frequently present-
ing symptom of BD in patients starting their disease
before the age of 16 years [14–17]. As ROA is not very
specific for BD, the expert group decided to add at least
one symptom from a list to consider the patient as eli-
gible to enter the PED-BD study. The list contained simi-
lar signs to those of the ISG criteria, but also included
vascular involvement and a family history of BD. At
mid-term of the study, we were able to assemble a
cohort of 110 patients most of them having only a few
symptoms at inclusion. Almost 20% of them had familial
history of BD, in accordance with the strong genetic
component demonstrated in PED-BD [18, 19]. The pre-
senting symptom was isolated ROA in 83% of the cases.
In the evolution, ROA was always present in patients
presenting at least three symptoms (data not shown). A
few patients entered into their disease with fever, uveitis
or neurological symptoms, but never with cutaneous
signs and only once with venous thrombosis. Skin le-
sions and uveitis were reported less frequently than in
adult BD (52 and 34%, respectively). Uveitis was signifi-
cantly more frequent in males and GU in females. Uveitis
had a severe course in 20% of the cases with reduced
visual acuity of <1/10. The male predominance of uveitis
has been reported in many paediatric series, also
emphasizing its severity [15, 19–21]. In addition, disease
FIG. 2 Clinical signs (percentages) at first visit, according to gender, in 106 PED-BD patients.
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TABLE 1 List of the main symptoms in addition to oral
aphthosis in patients classified as definite and probable
by the committee of experts
Confirmed (n=30) Probable (n=18)
GU* 21 7
Skin lesions** 22 3
Uveitis 16 6
Arthralgia/arthritis 11 7
Gastrointestinal 12 6
Neurological*** 12 3
Vascular 7 1
Fever 13 6
Significant values: *P= 0.03; **P= 0.0001; ***P= 0.09.
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was active in most cases, while 60% of patients were
receiving immunosuppressive treatment. Furthermore,
during a 1-year follow-up, one-third of patients had at
least one new symptom including three cases of uveitis.
These data are in accordance with the study of Yazici
et al. [8], which showed a more severe BD course in
patients with younger onset (before 25 years) of their
disease as compared with later-onset ones.
BD was confirmed in 30/48 (62%) patients. The number
of symptoms associated with BD confirmation was three
or more (including ROA), P= 0.0005. Clinical signs signifi-
cantly associated with BD confirmation were GU (P= 0.03)
and skin lesions (P= 0.0001), and were very concordant
with the ISG criteria. However, there was no clear asso-
ciation of BD confirmation with uveitis (P= 0.18), neuro-
logical signs (P= 0.09) and vascular involvement (P= 0.23).
In conclusion, at this initial step of the study, the expert
committee has classified the majority of patients in the BD
group although they did not all meet the BD classification
criteria at inclusion.
Rheumatology key messages
. All paediatric patients with suspected BD do not
meet the international criteria.
. Having at least three symptoms was significantly
associated with classification as definite BD by
the expert committee.
. Skin lesions and GU were significantly associated
with classification as definite BD.
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